Revelation Biosciences, Inc. (REVB): R&D Expense
$4.06M
Year ended 2025-12-31
$5.18M
Trailing 12 months to 2026-06-30
-8.9%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.06M | +14.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $3.55M | -14.4% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $4.15M | -22.9% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $5.38M | -22.2% | 2024-09-23, From 2022-01-01 |
| 2021-12-31 | $6.91M | n/a | 2023-03-30, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $4.06M | +14.5% |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $2.99M | n/a |
| NewcelX Ltd. (NCEL) | 2025-12-31 | $1.13M | +13.5% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $1.14M | -90.3% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $6.80M | -68.4% |
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $1.72M | -48.0% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $368.2K | -52.2% |
| Anebulo Pharmaceuticals, Inc. (ANEB) | 2025-06-30 | $4.30M | +21.2% |
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $11.51M | -28.6% |
Compare REVB, CURX, NCEL, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗